FDA Clears First Treatment Aimed at Schizophrenia’s Negative Symptoms — and It’s an App

DocSana News · October 12, 2026 · 4 min read

Antipsychotic medication can quiet hallucinations and delusions, but it has never specifically targeted the other half of schizophrenia: the loss of motivation, pleasure, and social drive. The FDA has now cleared a prescription app for exactly that — with honest limits worth understanding.

What happened

On October 5, 2026, Click Therapeutics announced that the FDA had cleared Motivista, a prescription digital therapeutic it developed with Boehringer Ingelheim, for the treatment of the negative symptoms of schizophrenia. The clearance covers adults whose positive symptoms (such as hallucinations and delusions) are clinically stable, and it is explicitly an add-on: the app is used alongside clinician-managed outpatient care, including antipsychotic medication — never instead of it.

Click describes Motivista as the first FDA-authorized treatment indicated specifically for these symptoms. No drug carries that indication, which is part of why this clearance drew attention well beyond the digital-health world.

What are “negative symptoms,” in plain language?

Schizophrenia is often pictured through its “positive” symptoms — experiences added on top of normal life, like hearing voices or holding fixed false beliefs. The “negative” symptoms are the opposite: things taken away. Motivation drains. Activities that used to bring pleasure stop registering. Social drive fades, speech can flatten, and starting even simple tasks becomes hard.

For many people, these losses are what most limit work, relationships, and independent living — and they commonly persist after medication has the positive symptoms under control. Families often describe this as the hardest part of the illness to watch, precisely because there has been so little to offer for it.

How the app works

Motivista is used on a smartphone for about 10 minutes a day over a 16-week program. It delivers established psychosocial techniques — lessons, goals, and daily check-ins drawn from behavioral and cognitive approaches — designed to help users reconnect effort with reward: setting a small goal, doing it, and registering the payoff. A clinician writes the prescription, a designated pharmacy fulfills it, and the patient activates the app with an access code.

What the trial showed — and what it didn’t

The clearance rests on CONVOKE, a randomized, double-blind Phase 3 trial of 457 adults who were stable on antipsychotic medication, published in JAMA Network Open in late September 2026. Half used Motivista and half used a control app with educational content but no therapeutic program. On the trial’s main measure — a clinician-rated scale of motivation and pleasure — the Motivista group improved more than the control group over 16 weeks, and the difference was statistically significant. The researchers characterize the size of the benefit as small to moderate, and the app was reported as well tolerated.

The balanced picture matters:

• The improvement showed up on the motivation-and-pleasure scale; expressive symptoms, such as flattened affect and reduced speech, did not differ significantly between the groups.
• Participants’ own overall ratings of improvement favored the app earlier in the trial but were no longer significantly different by week 16.
• The trial enrolled a selected group — stable outpatients with housing, a smartphone, and internet access — so results may not generalize to people in more unstable situations.
• How long any benefit lasts after the 16-week program ends is not yet established in the published record.

In other words: a real, regulated first — and a modest one. That combination is still meaningful for a symptom domain that previously had no specifically indicated treatment at all.

What it means for patients in Austin

Not much changes today. Click says the product is being prepared for broader availability, and it has not yet announced a launch date, a price, or insurance coverage — and coverage will likely decide how many people can actually get it, since many people living with schizophrenia rely on public insurance. If you or a family member lives with schizophrenia, the practical step is simple: ask your psychiatrist about it at your next visit, and do not change any medication based on news coverage. Negative symptoms also deserve a direct conversation in their own right — sometimes what looks like a negative symptom turns out to be depression, a medication side effect, or another treatable cause your care team can address now.